Plavix combination drug market emerging as blue chip

Many major Korea pharmaceutical manufacturers are poised to introduce a combination product of Plavix and Aspirin (clopidogrel + acetylsalicylate 75 mg) with the hope of acquiring large share of the blockbuster drug as the Korea unit of Sanofi Aventis announced its intention not to develop the combination product due to more strict regulatory procedures.

Currently, Chong Kun Dang Pharmaceuti...